HMNC Brain Health Appoints Dr. Bertram Müller-Myhsok as Head of Precision Psychiatry
MUNICH, Germany, Feb. 24, 2022 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC'' or the “Company”), a clinical stage biopharmaceutical company pioneering the development of personalized therapies in psychiatry, announced today the appointment of Dr. Bertram Müller-Myhsok as its new Head of Precision Psychiatry, effective March 1, 2022. The Head of the Statistical Genetics Research Group at Max-Planck-Institute of Psychiatry in Munich has signed an additional contract with HMNC Brain Health next to his position at the Max-Planck-Institute. In his new role, Dr. Müller-Myhsok will help the Company to accelerate the development of differentiated treatment options through the combination of novel interventions with precision applications.